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ABSTRACT Pyridoxal 5=-phosphate (PLP) is a coenzyme synthesized by all forms of life. Relevant to the work reported here is the
mechanism of the PLP-dependent threonine/serine dehydratases, which generate reactive enamine/imine intermediates that are
converted to keto acids by members of the RidA family of enzymes. The RidA protein of Salmonella enterica serovar Typhimu-
rium LT2 is the founding member of this broadly conserved family of proteins (formerly known as YjgF/YER057c/UK114). RidA
proteins were recently shown to be enamine deaminases. Here we demonstrate the damaging potential of enamines in the ab-
sence of RidA proteins. Notably, S. enterica strains lacking RidA have decreased activity of the PLP-dependent transaminase B
enzyme IlvE, an enzyme involved in branched-chain amino acid biosynthesis. We reconstituted the threonine/serine dehydra-
tase (IlvA)-dependent inhibition of IlvE in vitro, show that the in vitro system reflects the mechanism of RidA function in vivo,
and show that IlvE inhibition is prevented by RidA proteins from all domains of life. We conclude that 2-aminoacrylate (2AA)
inhibition represents a new type of metabolic damage, and this finding provides an important physiological context for the role
of the ubiquitous RidA family of enamine deaminases in preventing damage by 2AA.
IMPORTANCE External stresses that disrupt metabolic components can perturb cellular functions and affect growth. A similar
consequence is expected if endogenously generated metabolites are reactive and persist in the cellular environment. Here we
show that the metabolic intermediate 2-aminoacrylate (2AA) causes significant cellular damage if allowed to accumulate aber-
rantly. Furthermore, we show that the widely conserved protein RidA prevents this accumulation by facilitating conversion of
2AA to a stable metabolite. This work demonstrates that the reactive metabolite 2AA, previously considered innocuous in the
cell due to a short half-life in aqueous solution, can survive in the cellular environment long enough to cause damage. This work
provides insights into the roles and persistence of reactive metabolites in vivo and shows that the RidA family of proteins is able
to prevent damage caused by a reactive intermediate that is created as a consequence of PLP-dependent chemistry.
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The classic view of metabolism holds that it is comprised ofdiscrete but integrated biochemical pathways that generate the
building blocks of life. A complex repertoire of regulatory systems
maintain metabolic homeostasis at the transcriptional, transla-
tional, and posttranslational level, in addition to ensuring the
availability of metals and cofactors that are required for enzyme
function. Disruption of any of these systems has deleterious con-
sequences on the growth and/or behavior of an organism. Meta-
bolic imbalance can also be caused by reactive metabolites gener-
ated nonenzymatically or as a part of normal metabolic pathways.
For instance, if left uncontrolled, reactive oxygen species (ROS)
generated during aerobic growth can damage DNA, proteins, lip-
ids, and cofactors. To meet the ROS challenge, organisms have
evolved peroxidases, catalases, and dismutases which prevent cell
death (1). Similarly, intermediates of other pathways can be
detrimental if they accumulate. For example, 2-keto-3-
deoxygluconate 6-phosphate (2KDGP), an intermediate in the Ent-
ner-Doudoroff pathway, and 5-aminoimidazole-4-carboxamide ri-
bonucleotide (AICAR), an intermediate in purine biosynthesis, can
inhibit central metabolic enzymes if they accumulate (2–6). Here, we
describe cellular damage caused by a reactive enamine, which is gen-
erated as an unavoidable consequence of a reaction mechanism
common to all organisms, and we demonstrate an important role
for the RidA protein in preventing cellular damage by this reactive
enamine.
Pyridoxal 5=-phosphate (PLP)-dependent threonine/serine
dehydratases (ammonia lyases; EC 4.3.1.19 and 4.3.1.17) are
found in all domains of life. These well-characterized enzymes
dehydrate threonine or serine to form the corresponding enamine
intermediates. The enamines subsequently tautomerize to imines,
which are then hydrolyzed nonenzymatically to form the final
keto acid products (7, 8). The bacterium Salmonella enterica has
two PLP-dependent threonine/serine dehydratases, the biosyn-
thetic IlvA enzyme, involved in isoleucine biosynthesis, and the
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catabolic TdcB enzyme, involved in the anaerobic catabolism of
threonine. IlvA and TdcB have the same biochemical activity and
catalytic mechanism, but IlvA has a regulatory domain that re-
sponds to isoleucine, while TdcB is not allosterically regulated (9,
10).
RidA is the founding member of a broadly conserved family of
proteins (formerly known as YjgF/YER057c/UK114) found in all
domains of life (11–14). We recently showed that RidA homologs
increase the rate of hydrolysis of the enamine/imine products gen-
erated by PLP-dependent dehydratases (15). Prior to the above
report, it was generally accepted that the hydrolysis of these inter-
mediates into keto acid products was nonenzymatic in vivo. Im-
portantly, the previous mechanistic studies were performed under
conditions in which the half-lives of the enamine/imine interme-
diates were relatively short (3 to 4 min for the threonine-derived
intermediates [16, 17] and 1.5 s for the serine-derived intermedi-
ates [18]). However, multiple metabolic phenotypes of an S. en-
terica ridA mutant (11, 12, 19–21) suggested that the reactive in-
termediate substrates of RidA accumulated in vivo to levels that
affected other areas of metabolism.
Notably, the activity of isoleucine transaminase B was de-
creased in strains lacking RidA in both S. enterica and Saccharo-
myces cerevisiae (12, 22). In S. enterica, the decrease in the specific
activity of transaminase B (IlvE) depended on the activity of IlvA
(12) but not its normal substrate, threonine (23). Thus, the pos-
sibility that the IlvA-dependent inhibition of IlvE could be exerted
when serine was the substrate was considered. There was prece-
dent for the inhibition of IlvE by 2-aminoacrylate (2AA), the
serine-derived enamine that could also be derived from the serine
analog and suicide inhibitor 3-chloro-L-alanine (3CA) (24). Al-
though the mechanism of IlvE inhibition by 3CA is unknown,
some insights were obtained from studies of other PLP-dependent
enzymes inhibited by 3CA (25–28) and other serine analogs (29–
34). In each of the above-mentioned studies, a 2AA intermediate
was generated in the active site of the PLP-dependent enzyme,
which led to the formation of a 2AA-PLP adduct covalently bound
to the enzyme (27, 32, 34–36). These studies suggested a possible
mechanism underpinning the phenotypes of S. enterica ridA
strains.
This study was initiated to probe the deaminase activity of
RidA in the context of cellular metabolism. Specifically, we sought
to define the mechanism responsible for the decreased IlvE activ-
ity in a ridA strain and to address how this mechanism was related
to the characterized in vitro activity of RidA. Data reported here
support a model in which the dehydration of serine by IlvA gen-
erates 2AA, which in turn modifies and inhibits cellular targets in
vivo in the absence of RidA. We suggest that the role for RidA in
cell physiology is to prevent metabolic damage caused by reactive
enamines and that the presence of such reactive molecules in all
forms of life could be a major selective pressure for the evolution
and conservation of RidA proteins.
RESULTS
Increased levels of threonine dehydratase TdcB diminish IlvE
activity. The decreased activity of isoleucine transaminase B
(IlvE) in a ridA strain depended on the activity of the biosynthetic
threonine dehydratase (IlvA), a PLP-dependent enzyme (12).
S. entericahas a second PLP-dependent threonine/serine dehydra-
tase, the catabolic enzyme TdcB, whose expression is inhibited in
the presence of molecular oxygen and in the presence of glucose
(10, 37). To determine the basis of the IlvA requirement, tdcB was
provided ectopically under the control of a constitutive lac pro-
moter in ridA and ridA strains, allowing for expression of TdcB
under the growth conditions used here. Isoleucine was added to
the growth medium to allosterically inhibit IlvA and thus differ-
entiate between the effects of the isozymes TdcB and IlvA. IlvE
activity was assayed in crude extracts of relevant strains, and the
data are shown in Table 1.
In a ridA strain, the ectopic expression of tdcB had no effect
on IlvE activity in the presence or absence of isoleucine. In con-
trast, in a ridA strain, ectopic expression of tdcB decreased the
activity of IlvE to 3% (30-fold) compared to that of the ridA
strain (2 versus 72 nmol 2-keto-3-methylvalerate [2KMV] · min1
mg1 of protein). Unlike the inhibition resulting from IlvA activ-
ity, TdcB-dependent inhibition was unaffected by the addition of
isoleucine. In the vector control experiments, IlvE activity in the
ridA strain was decreased to 25% (4-fold) of that in the ridA
strain (18 versus 73 nmol 2KMV · min1 mg1). This decrease was
eliminated by the presence of isoleucine in the medium due to
allosteric inhibition of IlvA (12). In total, these data indicated that
in the absence of RidA in vivo, IlvE could be inhibited by two
distinct PLP-dependent threonine dehydratases.
PLP-dependent threonine/serine dehydratases inhibit IlvE
activity in vitro.The threonine/serine dehydratase-dependent in-
hibition of IlvE was reconstituted in vitro. Based on previous in
vivo data, serine was expected to be the relevant substrate for IlvA
in the context of inhibiting IlvE (23). To test whether IlvA and
serine could produce an intermediate that would inhibit IlvE, pu-
rified IlvE, IlvA, and L-serine were incubated together. Control
reaction mixtures lacked either IlvA or serine, and alternatively,
serine was replaced with L-threonine in the reaction mixture. The
reaction mixtures were preincubated at pH 9.0 to maximize the
half-lives of the intermediate metabolites formed in the dehydra-
tion reaction (15, 17, 38) at 37°C for 2 h (to allow ample time for
the intermediate to affect IlvE). After the preincubation period,
IlvE activity was assayed from each reaction by quantifying the
conversion of [14C]isoleucine to [14C]2KMV (Fig. 1).
Preincubation of IlvE with IlvA and serine decreased the activ-
ity of the enzyme to 24% of that of the IlvE protein incubated in
the absence of IlvA and serine (4 versus 18 mol
2KMV · min1 mg1) (Fig. 1A). Significantly, both serine and IlvA
were required to decrease IlvE activity. Further, IlvE was not in-
hibited by incubation with pyruvate, a product of serine deami-
nation, or when threonine was substituted for serine. Collectively,
these data suggested that IlvE inhibition was caused by an inter-
TABLE 1 IlvE activity is decreased in a ridA strain by serine/threonine
dehydratasesa
Relevant genotype
IlvE sp act (nmol 2KMV · min1
mg1 protein) in indicated medium
Minimal Minimal isoleucine
ridA pSU18 (empty) 73 9 52 2
ridA pSU18 (empty) 18 5 51 11
ridA pSU18-tdcB 72 8 77 6
ridA pSU18-tdcB 2 4 6 3
a Cells were grown in the indicated media, and IlvE activity was measured in
permeabilized cells as described in Materials and Methods. IlvE specific activity is
expressed in nmol 2KMV · min1 mg1 protein; shown are averages and standard
deviations of results from three biological replicates.
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mediate metabolite derived from serine by IlvA activity. Providing
TdcB instead of IlvA produced a similar result, with IlvE activity
decreasing to 14% of that found in the reaction mixtures lacking
TdcB. Taken together, the above data suggested that 2AA was
likely the reactive species generated by IlvA and TdcB and that
2AA inactivated IlvE.
RidA prevents IlvA-dependent inhibition of IlvE.The system
described above reconstituted one phenotype of a ridA strain,
namely, the serine/threonine dehydratase-dependent inhibition
of IlvE. Purified S. enterica RidA was added to the in vitro assay to
define the physiological relevance of this system. The presence of
RidA in the reaction mixture dramatically decreased the negative
effect of serine and IlvA on IlvE activity (Fig. 1B). The presence of
RidA in the reaction mixture restored IlvE activity from 20% to
87% of those of the uninhibited control reaction mixtures (3 ver-
sus 14 mol KMV min1 mg1, respectively). RidA homologs
from the archaeon Pyrococcus furiosus (PF0668), cucumber plant
Cucumis sativus (ChrD), and Homo sapiens (UK114) were all pro-
ficient at preventing the dehydratase-dependent inhibition of IlvE
(Fig. 1B). These results showed that, like other activities of RidA
(15), the function of RidA that protected IlvE was conserved
across all domains of life.
The suicide inhibitor 3CA has been shown to work via a 2AA
attack on the active site of PLP enzymes (27, 32, 34–36). The
presence of 3CA decreased IlvE activity to 5% of that of the unin-
hibited control (Fig. 2). While the reactive molecule derived from
both 3CA and IlvA/serine is expected to be 2AA, RidA had no
effect on the inhibition of IlvE by 3CA (Fig. 2). These data ap-
peared to distinguish the two mechanisms of inhibition. Consis-
tently with previous reports (25–28), these data suggested that the
3CA-derived 2AA was generated within the same active site that it
targeted; however, IlvA/serine-derived 2AA was generated in the
active site of the IlvA dehydratase, was released, and targeted the
active site of a different protein (IlvE). Together, these data sup-
ported the conclusion that RidA acted on free 2AA.
Modification with 3CA or IlvA and serine leads to a 317-Da
adduct on IlvE. A mass spectrometry approach was used to char-
acterize the protein modification generated by 2AA. Purified IlvE
protein was either left untreated or incubated with 3CA or IlvA
and serine. The resulting samples were subjected to intact-protein
electrospray ionization-time of flight mass spectrometry (ESI-
FIG 1 IlvE activity is inhibited by serine and IlvA. IlvE assays were performed
using a radioactive assay as described in Materials and Methods. (A) IlvE assays
were performed in the presence of IlvA, serine (Ser), pyruvate (Pyr), or thre-
onine (Thr), as indicated. (B) RidA homologs were added to IlvE that had been
preincubated with IlvA and serine (Ser), as indicated. RidA homologs tested
were from S. enterica (S.e.), P. furiosus (P.f.), C. sativus (C.s.), and H. sapiens
(H.s.). Shown are averages and ranges from two replicates for each condition
(ranges, 1 in all cases). Each assay was performed independently at least
twice.
FIG 2 3CA inhibits both wild-type IlvE and IlvEE38A activity. IlvE assays were
performed with pure protein using DNPH derivatization and subsequent or-
ganic extraction to quantify the product 2KMV as described in Materials and
Methods. Wild-type IlvE and IlvEE38A were assayed in the absence and pres-
ence of the inhibitor 3CA and RidA as indicated. Shown are averages and
ranges from two replicates for each condition (ranges, 1 in all cases). Each
assay was performed independently at least twice.
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TOF MS) analysis (Fig. 3). In all cases, a peak close to the expected
mass for IlvE (35,072 Da) was observed. Significantly, the IlvE
protein that was incubated with 3CA had a species with a higher
mass (an additional 317 Da) than the expected IlvE peak (Fig. 3A
and B). This species was not present in the IlvE sample from a
control reaction mixture lacking serine. The sample incubated
with IlvA/serine also had a peak with a mass of 317 mass units
more than the parental IlvE peak (Fig. 3C and D). When IlvE
lacking PLP was treated with 3CA, only a single peak with the IlvE
mass was visible (data not shown), demonstrating that PLP was
required for the modification. Together, these data suggested that
the same protein modification was generated on IlvE by 3CA or
IlvA/serine. These data were also consistent with IlvE being inhib-
ited by a mechanism involving a covalent adduct of 2AA and PLP
similar to those implicated in the suicide inhibition of other PLP-
dependent enzymes (27, 32, 34–36).
A317-Damodification is also foundonproteinpurified from
a ridA strain. To confirm that the in vitro reconstitution of IlvA-
dependent inhibition of IlvE was connected to the phenotypes of
ridA strains, IlvE protein was isolated from both ridA and ridA
strains. To maximize detection of any modification, TdcB was
overproduced in the strains from which IlvE was purified. After
purification, the IlvE protein isolated from the ridA strain had
80% the specific activity of the IlvE protein isolated from the
ridA strain. The reduced magnitude of
the inhibition was due to the expression
of IlvE above chromosomal levels to fa-
cilitate purification and was consistent
with previous results that showed that
the deleterious effect on IlvE was titrat-
able (12). Both IlvE protein preparations
were analyzed by mass spectrometry. In
both samples a peak of the appropriate
size for the intact IlvE protein was de-
tected (~34,957 Da). However, in the
sample isolated from the ridA strain, a
protein species that was 317-Da larger
(35,274 Da) was also detected (Fig. 3E
and F). Significantly, this peak was not
present in the protein sample that was
purified from the ridA strain. These two
protein preparations were also analyzed
by nanoESI ultra-high-resolution quad-
rupole TOF MS (QTOF MS), and the
presence of the minor 317-Da peak was
confirmed in the IlvE purified from the
ridA strain and was not found in the IlvE
purified from the ridA strain. These re-
sults supported the conclusion that in
strains lacking RidA, the 2AA generated
by IlvA accumulated to levels that were
sufficiently high to modify IlvE by the
mechanism observed in vitro.
Properties of the posttranslational
modification suggest a 2AA-PLP ad-
duct. Based on the 317-Da mass differ-
ence between the modified and unmodi-
fied IlvE enzymes, and considering
previously described modifications of
PLP-dependent enzymes, we concluded
that the modification on IlvE was a 2AA-PLP adduct. The mech-
anisms described for the inactivation of PLP enzymes by 3CA gave
two possible scenarios for a 2AA-PLP adduct on IlvE. In the first
scenario, characterized with the PLP-dependent enzyme alanine
racemase, 2AA attacks the PLP bound to the active-site lysine
residue, generating a pyruvate-PLP adduct covalently bound to
the active-site lysine and preventing further chemistry by the en-
zyme (27, 30, 31, 39). This mechanism resulted in an adduct that
added 319 Da to the mass of the unmodified protein and could be
removed intact from the protein with base treatment (27). Here,
IlvE protein that had been incubated with either 3CA or serine/
IlvA was treated with base, but it failed to release a stable product
(data not shown).
Alternatively, a 2AA-PLP adduct could be formed as an exter-
nal aldimine in the same way that PLP reacts with other nitrogen-
containing substrates. The resulting 2AA-PLP can be attacked by a
nonlysine nucleophilic residue in the active site, resulting in at-
tachment of the adduct to this residue (Fig. 4A) (26, 32–36). This
second mechanism would yield a modification with a mass of
317 Da when fully protonated for mass spectral analysis and allow
for the loss of a proton from the enzyme during the nucleophilic
attack. As shown in Fig. 3, whole IlvE protein treated with IlvA/
serine or 3CA resulted in a product with an additional 317 Da, but
efforts using standard methods of trypsin or endoproteinase
FIG 3 IlvE proteins are modified by 2AA. IlvE protein samples were subjected to the relevant treatment
prior to MS analysis as described in Materials and Methods. (A) Untreated; (B) incubated with 3CA; (C)
untreated; (D) incubated with IlvA/serine; (E) IlvE purified from the ridA strain; (F) IlvE purified from
a ridA strain. Samples in panels A, B, E, and F were precipitated with acetone and resuspended in acid
before mass spectral analysis, while samples in panels C and D were separated by LC before mass
analysis. In samples A, C, and E, no species with an additional 317 amu was visible.
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Glu-C digestion failed to detect the modified fragment. These re-
sults suggested that the relevant adduct was not stable in one or
more steps of the digestion process.
Inspection of the crystal structure of the E. coli IlvE enzyme
(1A3G [40; http://www.pdb.org/pdb/home/home.do.]) showed
that the closest nucleophilic residue to the active portion of the
PLP molecule was Glu38. This residue was changed to an alanine
by site-directed mutagenesis, generating variant protein IlvEE38A.
The IlvEE38A variant was purified from a ridA strain and incu-
bated with 3CA. If Glu38 were the site of the 2AA-PLP modifica-
tion, the IlvEE38A variant would be resistant to 3CA inhibition.
Though the IlvEE38A variant had a reduced specific activity, the
activity was still eliminated by incubation with 3CA (Fig. 2), indi-
cating that Glu38 was not a functionally significant site of modi-
fication. Consistently, when the untreated and 3CA-exposed
IlvEE38A variant were subjected to mass spectral analysis, the vari-
ant exposed to 3CA had a species that was 317-Da larger than the
untreated protein (see Fig. S1 in the supplemental material). The
activity of the IlvEE38A variant was also inhibited by incubation
with IlvA and serine (data not shown), indicating that the Glu38
residue was not the site of the modification generated by IlvA/
serine. Other nucleophilic residues in the active site are implicated
in binding the PLP cofactor, and these were not substituted due to
their expected requirement for activity (41).
DISCUSSION
The mechanism of PLP-dependent serine/threonine dehydratases
involves the formation of reactive enamine/imine intermediates
that are hydrolyzed to keto acid products by water. To our knowl-
edge, an impact of these metabolites in vivo has not been reported.
FIG 4 Distally generated 2AA modifies PLP enzymes unless it was removed by RidA. Both the inhibition of a PLP enzyme by 3CA and the generation of 2AA
and its three fates in vivo are schematically represented. (A) Inhibition of PLP-dependent enzyme IlvE by the suicide substrate 3CA. In step 1, IlvE forms an
internal aldimine between PLP and the suicide substrate 3CA. In step 2 the 3CA is dechlorinated, forming a 2AA-PLP intermediate that is attacked by a
nucleophilic residue (Nu) in the IlvE active site. Step 3 results in an inactive IlvE enzyme, with 2AA-PLP attached to a nucleophilic residue. (B) Schematic of the
PLP-dependent mechanism of serine dehydration by IlvA that results in the formation of 2AA. In step 4, IlvA forms an internal aldimine between PLP and serine.
In step 5, the serine is dehydrated, generating 2AA in the enzyme active site. In step 6, the 2AA is released from the PLP into solution. (C) Three fates of 2AA in
vivo. Step 7a reflects the hydrolysis of 2AA that can occur on the enzyme or in solution. Step 7b depicts the RidA-assisted hydrolysis of 2AA. Step 7c depicts the
attack of the IlvE active site by 2AA and the resulting modification, which is also generated by 3CA attack in panel A. Purple shading, IlvE enzyme; blue shading,
IlvA enzyme; green shading, RidA enzyme; red shading, reactive metabolite 2-aminoacrylate (2AA).
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A role for reactive enamines like 2AA in the cell may have been
overlooked because these metabolites are easily hydrolyzed in
vitro and thus not expected to persist in an aqueous solution. Here,
we showed that enamine/imine metabolites attacked the active
site of an enzyme distinct from the dehydratase that formed them,
both in vitro and in vivo. The ability of RidA proteins to prevent
this damage supported the conclusion that this family of proteins
has an important role in preventing damage from enamines. Evi-
dence that isoleucine transaminase B (IlvE) was damaged by 2AA
in strains lacking RidA (Fig. 3) validated the physiological signif-
icance of the data from in vitro experiments (Fig. 1) and empha-
sized the significance of this finding to our understanding of both
mechanistic biochemistry and cellular physiology.
The data presented herein warrant a paradigm shift in our
understanding of the persistence of enamine species in vivo
(Fig. 4). Previous reports described how 3CA and related com-
pounds damage PLP-dependent enzymes in vitro via the forma-
tion of 2AA (25–34). This scenario as it relates to IlvE (Fig. 4A)
leads to a 2AA-PLP adduct attached to a nucleophilic residue in
the IlvE active site. In contrast to this situation, our data showed
that when the PLP-dependent threonine dehydratase IlvA dehy-
drated serine (Fig. 4B), the resulting 2AA product had three po-
tential fates (Fig. 4C). First, the canonical attack on 2AA by water
results in the formation of pyruvate. Second, 2AA released into
solution can be deaminated by the RidA enzyme (15). Third, in
the absence of RidA, the free 2AA is able to modify and thus
inactivate IlvE. To our knowledge, this is the first evidence of 2AA
inactivating a site distinct from the enzymatic active site that gen-
erated it. Previously, we showed that the reduced specific activity
of IlvE that is found in a ridA strain required the activity of IlvA
(12). Those data, in combination with the results here, demon-
strated that endogenously generated 2AA inactivates enzymes in
vivo. These findings demonstrate that the reactive enamine inter-
mediates formed as part of PLP-dependent chemistry can persist
in the cellular environment long enough to damage target en-
zymes. Although it was formally possible that the 2AA was chan-
neled to the IlvE active site and not present in the cellular milieu,
the finding that other PLP-dependent enzymes, including alanine
racemase (Alr), are similarly damaged by 2AA minimizes this pos-
sibility (J. M. Flynn and D. M. Downs, unpublished data). Thus, in
total, the in vivo and in vitro data showed that the presence of RidA
prevented damage by free 2AA. These results allow the conclusion
that the enamine deaminase activity of RidA has a critical role in
cell physiology.
We suggest that the RidA family of proteins comprises a dam-
age prevention system that intercepts reactive metabolites to pre-
empt damage to cellular proteins. The RidA protein family is
broadly conserved and consists of both high- and low-identity
members (42). High-identity members from all domains are func-
tionally interchangeable in vivo and in vitro (15, 21). We suggest
that the high-identity RidA proteins have a housekeeping role in
preventing damage from enamines generated by PLP-dependent
enzymes in central metabolism. The conservation of RidA sug-
gests that damage from 2AA may be a universal challenge that
organisms must manage. IlvA is not the only enzyme whose mech-
anism could produce free 2AA in vivo. Organisms have other PLP
enzymes whose reaction mechanisms may involve 2AA derived
from serine, cysteine, tryptophan, or other metabolites (43–47).
PLP-dependent enzymes are ubiquitous, and the need for this
cofactor is a selective pressure for the evolution of RidA enzymes
to avert damage caused by enamine/imine intermediates.
There are examples of high-identity RidA homologs in operons
with biosynthetic genes that include a PLP-dependent serine/thre-
onine dehydratase (48, 49) and low-identity RidA homologs that
exist in pathways generating reactive enamine intermediates dis-
tinct from 2AA (50–56). These findings suggest that some RidA
homologs may have a different function and are thus clustered
with genes involved in pathways that produce specific enamines or
other reactive metabolites.
The results of in vivo genetic analyses, conservation of the pro-
tein family, and a preliminary bioinformatic analysis emphasized
a role for the RidA protein family beyond protecting only IlvE.
Phenotypes of a ridA mutant of S. enterica include sensitivity to
serine and cysteine, the inability to use pyruvate or glycerol as a
carbon source, decreased activity of IlvE, decreased activity of Alr,
and the ability to synthesize the thiamine precursor phosphoribo-
syl amine (PRA) by a novel mechanism (11, 12, 19, 20; J.M. Flynn
and D.M. Downs, unpublished data). PRA formation required the
2-aminocrotonate intermediate of threonine dehydration, while
the decrease in both IlvE and Alr required the 2AA intermediate of
serine dehydration (15, 21, 57). The consequences of the accumu-
lation of these reactive metabolites were apparent only in the ab-
sence of RidA. It is not yet clear how many of the metabolic phe-
notypes of a ridA strain require the activity of a serine/threonine
dehydratase or how many target proteins of 2AA modification
exist. Insights generated by the current study will facilitate our
ability to define additional metabolic phenotypes of a ridA strain
on a mechanistic level.
MATERIALS AND METHODS
Strain construction. The gene encoding IlvE was cloned into plasmid
pET28b() (Novagen) at NcoI and XhoI sites, creating a pET28-ilvE
construct that directed the synthesis of IlvE with a hexahistidine tag fused
to its C terminus (IlvE-H6). Strains used for the overexpression of ilvE
were derived from SB300A1 (58), a derivative of S. enterica that carries a
chromosomally borne gene for T7 polymerase under the control of the
arabinose-inducible PBAD promoter (aadA::araC-PBAD T7 pol). Strain
SB300A1carrying plasmid pET28-ilvE was named DM13730. The
pET28-ilvE plasmid was also moved into ridA and ridA1::Tn10d (tet)
derivatives of strain SB300A1 that harbored plasmid pSU18-tdcB. The
resulting strains were named DM13914 (ridA) and DM13915 (ridA),
respectively.
To generate the IlvEE38A variant, site-directed mutagenesis of pET28-
ilvE was performed using the QuikChange Lightening (Agilent) kit ac-
cording to the manufacturer’s protocol. The resulting plasmid was intro-
duced into the aadA::araC-PBAD T7 pol strain SB300A1, generating
strain DM13974.
Protein purification. The purifications of the S. enterica IlvA and
RidA proteins and RidA homologs were described elsewhere (15, 21). To
purify wild-type IlvE and the IlvEE38A proteins, strains DM13730 and
DM13974 were grown in 3 liters of superbroth (32 g tryptone, 20 g yeast
extract, 5 g sodium chloride, and 1 ml 5 N sodium hydroxide per liter)
containing kanamycin (50 mg/liter). The cultures were incubated at 37°C
with shaking until they reached an optical density (650 nm) of 0.35, at
which time ilvE expression was induced with 0.2% (wt/vol) L-()-
arabinose (herein arabinose) and 0.2 mM isopropyl--D-thiogalactoside
(IPTG). Cells were grown for 3 more hours and then harvested by centrif-
ugation. Alternatively, strains DM13914 and DM13915 were grown in
4.5 liters of minimal no-carbon E medium (59) containing glucose
(22 mM), MgSO4 (1 mM), trace minerals (adapted from reference 60),
histidine (100 M), pantothenate (100 M), kanamycin (50 mg/liter),
and chloramphenicol (5 mg/liter). In this case, there was no addition of
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arabinose or IPTG and ilvE expression was at a basal level from the T7
promoter. These cultures were grown for 16 h at 37°C, and then the cells
were harvested by centrifugation.
Cell pellets were resuspended in potassium phosphate buffer (50 mM,
pH 7.7) containing NaCl (100 mM), imidazole (5 mM), and glycerol
(10%, vol/vol) and disrupted using a French press. Cell-free extracts were
clarified by centrifugation (48,000 g for 45 min) and applied to nickel-
nitrilotriacetic (Ni-NTA) Superflow resin. The relevant protein was puri-
fied according to the manufacturer’s protocol (Qiagen) using column
chromatography and an imidazole gradient. The purified protein was
concentrated ~5-fold and desalted into potassium phosphate buffer
(50 mM, pH 7.7) containing NaCl (100 mM) and glycerol (10%, vol/vol)
using a PD-10 Sephadex G-25M column developed by gravity (GE
Healthcare).
IlvE enzyme activity assays. (i) Nonradioactive assays.Assays of IlvE
activity were performed with permeabilized cells as described previously
(12, 61). Briefly, cells were grown in minimal medium with glucose
(11 mM) as the carbon source, pelleted, and resuspended in potassium
phosphate buffer (pH 8). An aliquot of cells was permeabilized by 10%
PopCulture (Novagen) in the presence of the assay reagents potassium
phosphate buffer (100 mM, pH 8), PLP (50 M), and 2-ketoglutarate
(10 mM). The substrate L-isoleucine (20 mM) was added to initiate reac-
tions. Alternatively, 0.5 g of purified IlvE protein was used in lieu of
permeabilized cells when assays were performed in the presence of the
inhibitor 3CA. The formation of product 2-keto-3-methylvalerate
(2KMV) was measured after 20 min by 2,4-dinitrophenylhydrazine
(DNPH) derivatization and subsequent organic extraction. Protein from
permeabilized cells was quantified by a bicinchoninic acid assay kit
(Pierce). IlvE activity was reported as nmol 2KMV · min1 mg1 protein.
(ii) Radioactive assays. Reaction mixtures containing potassium
phosphate (50 mM, pH 9.0), PLP (50 M), 2-ketoglutarate (12.5 mM),
IlvE (0.75 g), IlvA (10 g), serine (50 mM), and RidA (16 g) as indi-
cated in the figures, were preincubated at 37°C for 2 h to allow for IlvE
inhibition. L-[U-14C]isoleucine (American Radiolabeled Chemicals) was
added to a final concentration of 5 mM (20 nCi) to initiate IlvE reactions.
Reaction mixtures were incubated for 15 min at 37°C, and reactions were
stopped by spotting 5 l (0.5 nCi) onto a prewashed polyethyleneimine
cellulose thin-layer chromatography plate. The plate was developed using
a butanol-acetic acid-water (4:2:1) mobile phase to separate [14C]isoleu-
cine from [14C]2KMV. The relative mobilities of radioactive spots were
detected using a Cyclone Storage Phosphor Screen (Packard Instrument
Company) and a Typhoon FLA 9000 scanner (GE Healthcare). The con-
centration of [14C]2KMV was quantified, and specific activity is reported
as mol of 2KMV · min1 mg1 IlvE.
Mass spectrometry analyses. Reaction mixtures containing potas-
sium phosphate buffer (50 mM, pH 9.0), PLP (33 M), IlvE (20 g), and
IlvA (1 g), with or without L-serine (100 mM), were incubated at 37°C
for 4 h. Alternatively, reaction mixtures containing potassium phosphate
buffer (50 mM, pH 9.0), PLP (33 M), IlvE (20 g), and 3CA (1 mM)
were incubated at 37°C for 3 h. Subsequent mass spectrometry (MS) anal-
yses were performed at the University of Wisconsin Biotechnology Cen-
ter. For IlvE proteins isolated from the ridA and ridA strains, 100 g of
treated protein was precipitated with acetone, and then samples were
resolubilized in acid before direct MS analysis. The 3CA-modified sample
and unmodified control were also treated with acetone and acid before
MS analysis. The serine-treated sample and control were chromatograph-
ically resolved with a Jupiter C4 300Å 50- by 2-mm column (Phenome-
nex) on an Agilent 1200 high-performance liquid chromatograph
(HPLC), using a linear gradient of 0.1% acetic acid in water and 0.1%
acetic acid in acetonitrile over 30 min. The mass spectrometer used was an
Agilent LC/TOF MS with electrospray ionization (ESI) used in positive-
ion mode. Acquired data were processed using Analyst QS 1.1 (build
9865) software (Agilent) to monitor masses observed in the range of 100
to 3,200 amu. Intact protein species deconvolution was carried out using
the ProteinApp module of Agilent BioConfirm software. An independent
verification of intact protein masses was carried out at the University of
Wisconsin—Madison School of Pharmacy Analytical Instrumentation
Center. Treated and untreated IlvE samples were dialyzed against ammo-
nium bicarbonate buffer (20 mM). Protein was then diluted 1:10 into 20%
acetonitrile with 0.1% formic acid and analyzed directly on a nanoESI
ultra-high-resolution QTOF MS (MaXis 4G) in positive-ion mode.
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